FibroBiologics Inc. is facing potential delisting from the Nasdaq Capital Market due to non-compliance with key listing requirements. The company failed to maintain a minimum market value of listed securities of $35 million for 30 consecutive trading days, as required by Nasdaq Listing Rule 5550(b)(2). Additionally, FibroBiologics has previously reported a deficiency related to the minimum bid price rule. The company has presented a plan to regain compliance, including a proposed reverse stock split, and is awaiting a decision from the Nasdaq Hearings Panel. There is no assurance that an extension will be granted or that the company's efforts will succeed in regaining compliance with Nasdaq's listing standards.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Fibrobiologics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001193125-26-041187), on February 06, 2026, and is solely responsible for the information contained therein.